Voya Investment Management LLC Sage Therapeutics, Inc. Transaction History

Voya Investment Management LLC

$79.9 Billion
Q3 2024

A detailed history of Voya Investment Management LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 34,636 shares of SAGE stock, worth $189,805. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,636

Previous 18,012 92.29%

Holding current value

$189,805

Previous $195,000 27.69%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $116,700 - $217,441	16,624 Added 92.29%	34,636 $249,000
Q2 2024 Dec 03, 2024	SELL	$10.58 - $17.9 $175,881 - $297,569	-16,624 Reduced 48.0%	18,012 $195,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $6,252 - $10,578	591 Added 3.39%	18,012 $195,000
Q1 2024 Dec 06, 2024	SELL	$18.62 - $26.95 $320,543 - $463,944	-17,215 Reduced 49.7%	17,421 $326,000
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $67,571 - $97,801	-3,629 Reduced 17.24%	17,421 $326,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $1.25 Million - $1.62 Million	-72,971 Reduced 77.61%	21,050 $456,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $321,801 - $941,003	19,212 Added 25.68%	94,021 $1.93 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $2.23 Million - $3.27 Million	54,970 Added 277.08%	74,809 $3.52 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $9,280 - $11,595	-249 Reduced 1.24%	19,839 $832,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $1.93 Million - $2.58 Million	-59,736 Reduced 74.83%	20,088 $786,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $393,068 - $542,611	14,283 Added 21.79%	79,824 $2.58 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $26,809 - $39,904	-873 Reduced 1.31%	65,541 $2.17 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $2.15 Million - $2.74 Million	58,124 Added 701.13%	66,414 $2.83 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $1,771 - $2,524	44 Added 0.53%	8,290 $367,000
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $10,976 - $15,858	200 Added 2.49%	8,246 $468,000
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $20,841 - $28,544	-295 Reduced 3.54%	8,046 $602,000
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $30,548 - $46,578	-523 Reduced 5.9%	8,341 $722,000
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $15,012 - $22,794	-365 Reduced 3.95%	8,864 $542,000
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $234,510 - $389,946	-9,037 Reduced 49.47%	9,229 $384,000
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $17,808 - $52,600	-681 Reduced 3.59%	18,266 $525,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $372,273 - $957,407	-6,186 Reduced 24.61%	18,947 $1.37 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $35,212 - $47,679	251 Added 1.01%	25,133 $3.53 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $182,001 - $211,102	-1,153 Reduced 4.43%	24,882 $4.56 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $149,895 - $274,604	-1,678 Reduced 6.05%	26,035 $4.14 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $38,675 - $65,943	-472 Reduced 1.67%	27,713 $2.66 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $208,546 - $255,250	-1,510 Reduced 5.09%	28,185 $3.98 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $39.2 Million - $49.1 Million	-279,268 Reduced 90.39%	29,695 $4.65 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $44.4 Million - $56.1 Million	291,884 Added 1709.02%	308,963 $49.8 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $63,998 - $176,376	1,054 Added 6.58%	17,079 $2.81 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $983,935 - $1.42 Million	16,025	16,025 $998,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Account

Voya Investment Management LLC Sage Therapeutics, Inc. Transaction History